Previous 10 | Next 10 |
Ritter Pharmaceuticals (NASDAQ: RTTR ): FY GAAP EPS of -$3.66 misses by $0.86. More news on: Ritter Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal disease...
SPI Energy (NASDAQ: SPI ) +115% on completing its previously announced second-stage acquisition of 100% of the equity interest of HELIOHRISI S.A. More news on: SPI Energy Co., Ltd., One Stop Systems, Inc., Superconductor Technologies Inc., Stocks on the move, Read more ...
Kopin (NASDAQ: KOPN ) -24% on secondary offering . More news on: Kopin Corporation, PHI, Inc., Yield10 Bioscience, Inc., Stocks on the move, Read more ...
Top-line Data Readout Expected in early Q4 2019 LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut micro...
LOS ANGELES, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an...
Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28 LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the ...
LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an ini...
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019 LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceutica...
LOS ANGELES, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an init...
News, Short Squeeze, Breakout and More Instantly...
Ritter Pharmaceuticals Company Name:
RTTR Stock Symbol:
NASDAQ Market:
LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction with Qualigen, Inc. is currently expected to close...
LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count certified by the inspector of election for the s...
Will These Penny Stocks Stay Below $2? Penny stocks are always considered high-risk, high-reward equities. But many investors still have a hard time with the standard definition of penny stocks . According to the Securities and Exchange Commission, penny stocks are shares of public companie...